UNSPSC 51111906: Pegaspargase

This classification denotes a protein synthesis inhibitor with the molecular formula C1377H2208N382O442S17, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7D96IR0PPM, more generally known as pegaspargase. European Medicines Agency schedules pegaspargase in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03666MIG. The term PEGASPARGASE is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 5, no. 3 1991, list 31.

UNSPSC 51111906 Pegaspargase is a Commodity code covering pharmaceutical procurement for state and local healthcare programs, specifically the leukemia treatment medication pegaspargase used in chemotherapy regimens. State and local healthcare agencies—principally state health and human services departments managing Medicaid, state employee health plans, and other public health programs—procure this specialty pharmaceutical through direct manufacturer contracts, pharmacy benefit managers, and group purchasing organizations. The Texas Health and Human Services Commission, a representative buyer under this code, recently issued a Request for Information to evaluate direct-to-manufacturer prescription fulfillment models that would establish contracted relationships outside traditional PBM and GPO channels, signaling a shift toward negotiated net pricing and outcomes-based agreements in specialty drug procurement.

The recent activity under this code centers on Texas, where the HHS Commission posted RFI No. HHS0017013 on April 3, 2026, seeking vendor capabilities for direct manufacturer relationships, negotiated net pricing models without rebates, and value-based contracting structures. The RFI marks an exploratory phase before formal competitive solicitation and does not specify budget allocation, award value, or timeline parameters; it functions as market intelligence gathering to inform subsequent RFP design. State health agencies pursuing specialty pharmaceutical contracting should monitor this RFI outcome and anticipate follow-on formal RFP activity from Texas HHS once vendor responses inform the state's direct-contracting strategy and implementation approach.